Involvement of the P2X7 purinergic receptor and c-Jun N-terminal and extracellular signal-regulated kinases in cyclooxygenase-2 and prostaglandin E2 induction by LL-37

Journal of Innate Immunity

Volumn 5, Issue 1, 2013, Pages 72-83

  Chotjumlong, Pareena ^c   Bolscher, Jan G ^a   Nazmi, Kamran ^a   Reutrakul, Vichai ^b   Supanchart, Chayarop ^d   Buranaphatthana, Worakanya ^d   Krisanaprakornkit, Suttichai ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Mahidol University   (Thailand)

^c Faculty of Medicine Chiang Mai University   (Thailand)

^d CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Cathelicidin; Cyclooxygenase 2; LL 37; Mitogen activated protein kinase; P2X7; Prostaglandin E2; Purinergic receptors

Indexed keywords

BETA DEFENSIN 3; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NEUTRALIZING ANTIBODY; PROSTAGLANDIN E2; PROTEIN P46; PURINERGIC P2X7 RECEPTOR; PROTEIN C JUN; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE BINDING PROTEIN; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; STRESS ACTIVATED PROTEIN KINASE; SULFONAMIDE;

ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FIBROBLAST; GINGIVA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; AMINO TERMINAL SEQUENCE; CELL CULTURE; ENZYME ACTIVATION; MOUTH CAVITY; MUCOSAL IMMUNITY; PROSTAGLANDIN SYNTHESIS; PROTEIN INDUCTION; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOLOGY; PERIODONTAL DISEASE;

ANTIMICROBIAL CATIONIC PEPTIDES; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; GINGIVA; HUMANS; IMMUNITY, MUCOSAL; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NITROBENZENES; PERIODONTAL DISEASES; RECEPTORS, PURINERGIC P2X7; SIGNAL TRANSDUCTION; SULFONAMIDES;

MLCS; MLOWN;

EID: 84872276132     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000342928     Document Type: Article

References (40)

1. Dale BA, Fredericks LP: Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr Issues Mol Biol 2005; 7: 119-133.
2. Weinberg A, Krisanaprakornkit S, Dale BA: Epithelial antimicrobial peptides: review and significance for oral applications. Crit Rev Oral Biol Med 1998; 9: 399-414. (Pubitemid 29402008)
3. Zanetti M: The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol 2005; 7: 179-196. (Pubitemid 41051685)
4. Frohm Nilsson M, Sandstedt B, Sørensen O, Weber G, Borregaard N, Ståhle-Bäckdahl M: The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 1999; 67: 2561-2566. (Pubitemid 29200519)
5. Murakami M, Ohtake T, Dorschner RA, Gallo RL: Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res 2002; 81: 845-850.
6. Puklo M, Guentsch A, Hiemstra PS, Eick S, Potempa J: Analysis of neutrophil-derived antimicrobial peptides in gingival crevicular fluid suggests importance of cathelicidin LL-37 in the innate immune response against periodontogenic bacteria. Oral Microbiol Immunol 2008; 23: 328-335. (Pubitemid 351832179)
7. Hosokawa I, Hosokawa Y, Komatsuzawa H, Goncalves RB, Karimbux N, Napimoga MH, Seki M, Ouhara K, Sugai M, Taubman MA, Kawai T: Innate immune peptide LL-37 displays distinct expression pattern from betadefensins in inflamed gingival tissue. Clin Exp Immunol 2006; 146: 218-225. (Pubitemid 44581336)
8. Türkoǧlu O, Kandiloǧlu G, Berdeli A, Emingil G, Atilla G: Antimicrobial peptide hCAP- 18/LL-37 protein and mRNA expressions in different periodontal diseases. Oral Dis 2011; 17: 60-67.
9. Türkoǧlu O, Emingil G, Kütükçüler N, Atilla G: Gingival crevicular fluid levels of cathelicidin LL-37 and interleukin-18 in patients with chronic periodontitis. J Periodontol 2009; 80: 969-976.
10. Wixted JJ, Fanning P, Rothkopf I, Stein G, Lian J: Arachidonic acid, eicosanoids, and fracture repair. J Orthop Trauma 2010; 24: 539-542.
11. Miller SB: Prostaglandins in health and disease: an overview. Semin Arthritis Rheum 2006; 36: 37-49. (Pubitemid 44128595)
12. Ricciotti E, FitzGerald GA: Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 986-1000.
13. Noguchi K, Shitashige M, Yanai M, Morita I, Nishihara T, Murota S, Ishikawa I: Prostaglandin production via induction of cyclooxygenase-2 by human gingival fibroblasts stimulated with lipopolysaccharides. Inflammation 1996; 20: 555-568. (Pubitemid 26361657)
14. Morton RS, Dongari-Bagtzoglou AI: Cyclooxygenase-2 is upregulated in inflamed gingival tissues. J Periodontol 2001; 72: 461-469. (Pubitemid 33664492)
15. Yucel-Lindberg T, Ahola H, Nilsson S, Carlstedt- Duke J, Modéer T: Interleukin-1 beta induces expression of cyclooxygenase-2 mRNA in human gingival fibroblasts. Inflammation 1995; 19: 549-560.
16. Abiko Y, Saitoh M, Nishimura M, Yamazaki M, Sawamura D, Kaku T: Role of beta-defensins in oral epithelial health and disease. Med Mol Morphol 2007; 40: 179-184. (Pubitemid 350277687)
17. Chotjumlong P, Khongkhunthian S, Ongchai S, Reutrakul V, Krisanaprakornkit S: Human beta-defensin-3 up-regulates cyclooxygenase-2 expression and prostaglandin E2 synthesis in human gingival fibroblasts. J Periodontal Res 2010; 45: 464-470.
18. Chamorro CI, Weber G, Grönberg A, Pivarcsi A, Ståhle M: The human antimicrobial peptide LL-37 suppresses apoptosis in keratinocytes. J Invest Dermatol 2009; 129: 937- 944.
19. den Hertog AL, van Marle J, van Veen HA, Van't Hof W, Bolscher JG, Veerman EC, Nieuw Amerongen AV: Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. Biochem J 2005; 388: 689-695. (Pubitemid 40839946)
20. Krisanaprakornkit S, Kimball JR, Weinberg A, Darveau RP, Bainbridge BW, Dale BA: Inducible expression of human beta-defensin 2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. Infect Immun 2000; 68: 2907-2915. (Pubitemid 30253871)
21. Montreekachon P, Chotjumlong P, Bolscher JG, Nazmi K, Reutrakul V, Krisanaprakornkit S: Involvement of P2X(7) purinergic receptor and MEK1/2 in interleukin-8 upregulation by LL-37 in human gingival fibroblasts. J Periodontal Res 2011; 46: 327- 337.
22. Noguchi K, Shitashige M, Endo H, Kondo H, Yotsumoto Y, Izumi Y, Nitta H, Ishikawa I: Involvement of cyclooxygenase-2 in seruminduced prostaglandin production by human oral gingival epithelial cells. J Periodontal Res 2001; 36: 124-130. (Pubitemid 33636985)
23. Krisanaprakornkit S, Kimball JR, Dale BA: Regulation of human beta-defensin-2 in gingival epithelial cells: the involvement of mitogen- activated protein kinase pathways, but not the NF- - B transcription factor family. J Immunol 2002; 168: 316-324. (Pubitemid 34014132)
24. Zuyderduyn S, Ninaber DK, Hiemstra PS, Rabe KF: The antimicrobial peptide LL-37 enhances IL-8 release by human airway smooth muscle cells. J Allergy Clin Immunol 2006; 117: 1328-1335. (Pubitemid 43795721)
25. Damer S, Niebel B, Czeche S, Nickel P, Ardanuy U, Schmalzing G, Rettinger J, Mutschler E, Lambrecht G: NF279: a novel potent and selective antagonist of P2X receptor- mediated responses. Eur J Pharmacol 1998; 350:R5-R6. (Pubitemid 28288320)
26. Pochet S, Tandel S, Querriére S, Tre-Hardy M, Garcia-Marcos M, De Lorenzi M, Vandenbranden M, Marino A, Devleeschouwer M, Dehaye JP: Modulation by LL-37 of the responses of salivary glands to purinergic agonists. Mol Pharmacol 2006; 69: 2037- 2046. (Pubitemid 43894323)
27. Preshaw PM, Heasman PA: Prostaglandin E2 concentrations in gingival crevicular fluid: observations in untreated chronic periodontitis. J Clin Periodontol 2002; 29: 15-20. (Pubitemid 41697729)
28. Kim HJ, Cho DH, Lee KJ, Cho CS, Bang SI, Cho BK, Park HJ: LL-37 suppresses sodium nitroprusside-induced apoptosis of systemic sclerosis dermal fibroblasts. Exp Dermatol 2011; 20: 843-845.
29. Chen X, Niyonsaba F, Ushio H, Nagaoka I, Ikeda S, Okumura K, Ogawa H: Human cathelicidin LL-37 increases vascular permeability in the skin via mast cell activation, and phosphorylates MAP kinases p38 and ERK in mast cells. J Dermatol Sci 2006; 43: 63-66. (Pubitemid 43817496)
30. Brandenburg LO, Jansen S, Wruck CJ, Lucius R, Pufe T: Antimicrobial peptide rCRAMP induced glial cell activation through P2Y receptor signalling pathways. Mol Immunol 2010; 47: 1905-1913.
31. Yin J, Yu FS: LL-37 via EGFR transactivation to promote high glucose-attenuated epithelial wound healing in organ-cultured corneas. Invest Ophthalmol Vis Sci 2010; 51: 1891-1897.
32. Pistolic J, Cosseau C, Li Y, Yu JJ, Filewod NC, Gellatly S, Rehaume LM, Bowdish DM, Hancock RE: Host defence peptide LL-37 induces IL-6 expression in human bronchial epithelial cells by activation of the NF- - B signaling pathway. J Innate Immun 2009; 1: 254-267.
33. Båge T, Lindberg J, Lundeberg J, Modéer T, Yucel-Lindberg T: Signal pathways JNK and NF- - B, identified by global gene expression profiling, are involved in regulation of TNF - -induced mPGES-1 and COX-2 expression in gingival fibroblasts. BMC Genomics 2010; 11: 241.
34. Lau YE, Rozek A, Scott MG, Goosney DL, Davidson DJ, Hancock RE: Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect Immun 2005; 73: 583-591. (Pubitemid 40041153)
35. Mookherjee N, Lippert DN, Hamill P, Falsafi R, Nijnik A, Kindrachuk J, Pistolic J, Gardy J, Miri P, Naseer M, Foster LJ, Hancock RE: Intracellular receptor for human host defense peptide LL-37 in monocytes. J Immunol 2009; 183: 2688-2696.
36. De Yang, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O: LL-37, the neutrophil granuleand epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000; 192: 1069-1074.
37. Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y, Yahata Y, Dai X, Tohyama M, Nagai H, Yang L, Higashiyama S, Yoshimura A, Sugai M, Hashimoto K: Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol 2005; 175: 4662- 4668. (Pubitemid 41362007)
38. Tomasinsig L, Pizzirani C, Skerlavaj B, Pellegatti P, Gulinelli S, Tossi A, Di Virgilio F, Zanetti M: The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner. J Biol Chem 2008; 283: 30471-30481.
39. Supanchart C, Thawanaphong S, Makeudom A, Bolscher JGM, Nazmi K, Kornak U, Krisanaprakornkit S: The antimicrobial peptide, LL-37, inhibits in vitro osteoclastogenesis. J Dent Res, E-pub ahead of print.
40. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B: Conformation- dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 1998; 273: 3718-3724. (Pubitemid 28109800)